KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) Gross Margin (2018 - 2025)

Castle Biosciences' Gross Margin history spans 7 years, with the latest figure at 78.95% for Q4 2025.

  • For Q4 2025, Gross Margin fell 230.0% year-over-year to 78.95%; the TTM value through Dec 2025 reached 79.37%, down 250.0%, while the annual FY2025 figure was 79.37%, 250.0% down from the prior year.
  • Gross Margin for Q4 2025 was 78.95% at Castle Biosciences, up from 77.48% in the prior quarter.
  • Across five years, Gross Margin topped out at 100.0% in Q3 2021 and bottomed at 75.17% in Q4 2022.
  • The 5-year median for Gross Margin is 81.09% (2023), against an average of 81.02%.
  • The largest annual shift saw Gross Margin soared 1626bps in 2021 before it tumbled -2394bps in 2022.
  • A 5-year view of Gross Margin shows it stood at 81.64% in 2021, then decreased by -8bps to 75.17% in 2022, then increased by 8bps to 81.21% in 2023, then rose by 0bps to 81.25% in 2024, then dropped by -3bps to 78.95% in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Gross Margin are 78.95% (Q4 2025), 77.48% (Q3 2025), and 79.55% (Q2 2025).